☰

Douglas K. Graham - Publications

Affiliations: 
2003-2015 Molecular Biology University of Colorado Anschutz Medical Campus, Denver, Aurora, CO 
 2015- Pediatrics Emory University, Atlanta, GA 
Area:
Molecular Biology, Cancer Biology, Pediatric Leukemia, Receptor Tyrosine Kinase
Tree Info Grants Similar researchers PubMed Report error

119 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 DeRyckere D, Huelse JM, Earp HS, Graham DK. TAM family kinases as therapeutic targets at the interface of cancer and immunity. Nature Reviews. Clinical Oncology. PMID 37667010 DOI: 10.1038/s41571-023-00813-7  0.372
2023 Kelvin JM, Chimenti ML, Zhang DY, Williams EK, Moore SG, Humber GM, Baxter TA, Birnbaum LA, Qui M, Zecca H, Thapa A, Jain J, Jui NT, Wang X, Fu H, ... ... Graham DK, et al. Development of constitutively synergistic nanoformulations to enhance chemosensitivity in T-cell leukemia. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 37543290 DOI: 10.1016/j.jconrel.2023.07.045  0.309
2022 Summers RJ, Jain J, Vasileiadi E, Smith B, Chimenti ML, Yeung TY, Kelvin J, Wang X, Frye SV, Earp HS, Tyner JW, Dreaden EC, DeRyckere D, Graham DK. Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia. Cancers. 14. PMID 36551626 DOI: 10.3390/cancers14246142  0.371
2022 Yan D, Huelse JM, Kireev D, Tan Z, Chen L, Goyal S, Wang X, Frye SV, Behera M, Schneider F, Ramalingam SS, Owonikoko TK, Earp HS, DeRyckere D, Graham DK. MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer. The Journal of Clinical Investigation. PMID 35708914 DOI: 10.1172/JCI150517  0.392
2021 Yan D, Earp HS, DeRyckere D, Graham DK. Targeting MERTK and AXL in Mutant Non-Small Cell Lung Cancer. Cancers. 13. PMID 34830794 DOI: 10.3390/cancers13225639  0.394
2021 Zheng H, Zhao J, Li B, Zhang W, Stashko MA, Minson KA, Huey MG, Zhou Y, Earp HS, Kireev D, Graham DK, DeRyckere D, Frye SV, Wang X. UNC5293, a potent, orally available and highly MERTK-selective inhibitor. European Journal of Medicinal Chemistry. 220: 113534. PMID 34038857 DOI: 10.1016/j.ejmech.2021.113534  0.392
2021 Huelse JM, Fridlyand DM, Earp S, DeRyckere D, Graham DK. Corrigendum to "MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system" [Pharmacology & Therapeutics 213 (2020) 107577]. Pharmacology & Therapeutics. 107822. PMID 33714535 DOI: 10.1016/j.pharmthera.2021.107822  0.386
2020 Lee-Sherick AB, Jacobsen KM, Henry CJ, Huey MG, Parker RE, Page LS, Hill AA, Wang X, Frye SV, Earp HS, Jordan CT, DeRyckere D, Graham DK. MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity. Jci Insight. 5. PMID 33268596 DOI: 10.1172/jci.insight.145847  0.711
2020 Huelse J, Fridlyand D, Earp S, DeRyckere D, Graham DK. MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system. Pharmacology & Therapeutics. 107577. PMID 32417270 DOI: 10.1016/J.Pharmthera.2020.107577  0.512
2020 Yan D, Huelse J, Parker R, Tan Z, Wang X, Frye SV, Earp HS, DeRyckere D, Graham DK. Abstract 1882: MERTK drives residual tumor growth in EGFR-mutated non-small cell lung cancer cells treated with osimertinib Cancer Research. 80: 1882-1882. DOI: 10.1158/1538-7445.Am2020-1882  0.512
2019 Green AL, DeSisto J, Flannery P, Lemma R, Knox A, Lemieux M, Sanford B, O'Rourke R, Ramkissoon S, Jones K, Perry J, Hui X, Moroze E, Balakrishnan I, O'Neill AF, ... ... Graham DK, et al. BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway. Oncogene. PMID 31844250 DOI: 10.1038/S41388-019-1125-7  0.386
2019 Ni F, Yu WM, Li Z, Graham DK, Jin L, Kang S, Rossi MR, Li S, Broxmeyer HE, Qu CK. Critical role of ASCT2-mediated amino acid metabolism in promoting leukaemia development and progression. Nature Metabolism. 1: 390-403. PMID 31535081 DOI: 10.1038/s42255-019-0039-6  0.314
2019 Da C, Zhang D, Stashko M, Vasileiadi E, Parker R, Minson KA, Huey MG, Huelse JM, Hunter D, Gilbert TSK, Norris-Drouin J, Miley M, Herring LE, Graves LM, DeRyckere D, ... ... Graham D, et al. Data-driven construction of anti-tumor agents with controlled polypharmacology. Journal of the American Chemical Society. PMID 31497954 DOI: 10.1021/Jacs.9B08660  0.483
2019 Holtzhausen A, Harris W, Ubil E, Hunter DM, Zhao J, Zhang Y, Zhang D, Liu Q, Wang X, Graham DK, Frye SV, Earp HS. TAM Family Receptor kinase inhibition reverses MDSC-mediated suppression and augments anti-PD-1 therapy in melanoma. Cancer Immunology Research. PMID 31451482 DOI: 10.1158/2326-6066.Cir-19-0008  0.494
2019 Yan D, Huelse J, Parker R, Wang X, Frye SV, Earp HS, DeRyckere D, Graham D. Abstract 4765: MERTK is a potential therapeutic target in osimertinib-resistant non-small cell lung cancer Cancer Research. 79: 4765-4765. DOI: 10.1158/1538-7445.Sabcs18-4765  0.494
2019 Smart SK, Rupji M, Dwivedi B, Kowalski J, DeRyckere D, Graham DK. Abstract 2879: TYRO3 is a potential therapeutic target in pediatric acute myeloid leukemia Cancer Research. 79: 2879-2879. DOI: 10.1158/1538-7445.Sabcs18-2879  0.483
2019 Barnes DE, Wang X, Frye SV, Earp HS, DeRyckere D, Graham DK. Abstract 2192A: Combined MERTK and ROCK1/2 inhibition as a potential therapeutic strategy for AML Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-2192A  0.309
2019 Summers RJ, Minson KA, Wang X, Frye SV, Earp HS, DeRyckere D, Graham DK. Abstract A35: MERTK and BCL-2 as potential therapeutic targets in early T-precursor acute lymphoblastic leukemia Cancer Research. 78. DOI: 10.1158/1538-7445.Pedca17-A35  0.479
2019 Minson KA, Vasileiadi E, Huey MG, Wang X, Frye SV, Earp HS, DeRyckere D, Graham DK. Abstract 3037: Stromal cell activation of MAPK signaling pathways mediates resistance to MERTK inhibition in acute myeloid leukemia Cancer Research. 79: 3037-3037. DOI: 10.1158/1538-7445.Am2019-3037  0.507
2018 Smart SK, Vasileiadi E, Wang X, DeRyckere D, Graham DK. The Emerging Role of TYRO3 as a Therapeutic Target in Cancer. Cancers. 10. PMID 30501104 DOI: 10.3390/Cancers10120474  0.477
2018 Sinik L, Minson KA, Tentler JJ, Carrico J, Bagby SM, Robinson WA, Karni R, Burstyn-Cohen T, Eckhardt SG, Wang X, Frye SV, Earp HS, DeRyckere D, Graham DK. Inhibition of MERTK promotes suppression of tumor growth in BRAF mutant and BRAF wild-type melanoma. Molecular Cancer Therapeutics. PMID 30482852 DOI: 10.1158/1535-7163.Mct-18-0456  0.468
2018 Lee-Sherick AB, Jacobsen KM, Henry CJ, Huey MG, Parker RE, Page LS, Hill AA, Wang X, Frye SV, Earp HS, Jordan CT, DeRyckere D, Graham DK. MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity. Jci Insight. 3. PMID 30385715 DOI: 10.1172/Jci.Insight.97941  0.788
2018 Zhao J, Zhang D, Zhang W, Stashko MA, DeRyckere D, Vasileiadi E, Parker RE, Hunter D, Liu Q, Zhang Y, Norris-Drouin JL, Li B, Drewry D, Kireev DB, Graham DK, et al. Highly selective MERTK inhibitors achieved by a single methyl group. Journal of Medicinal Chemistry. PMID 30347155 DOI: 10.1021/Acs.Jmedchem.8B01229  0.433
2018 Yan D, Parker RE, Wang X, Frye SV, Earp HS, DeRyckere D, Graham DK. MERTK promotes resistance to irreversible EGFR tyrosine kinase inhibitors in non-small cell lung cancers expressing wild-type EGFR-family members. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30194074 DOI: 10.1158/1078-0432.Ccr-18-0040  0.461
2018 McDaniel NK, Cummings CT, Iida M, Hulse J, Pearson HE, Vasileiadi E, Parker RE, Orbuch RA, Ondracek OJ, Welke NB, Kang GH, Davies KD, Wang X, Frye SV, Earp HS, ... ... Graham DK, et al. MERTK mediates intrinsic and adaptive resistance to AXL-targeting agents. Molecular Cancer Therapeutics. PMID 30093568 DOI: 10.1158/1535-7163.Mct-17-1239  0.766
2018 Law LA, Graham DK, Di Paola J, Branchford BR. GAS6/TAM Pathway Signaling in Hemostasis and Thrombosis. Frontiers in Medicine. 5: 137. PMID 29868590 DOI: 10.3389/Fmed.2018.00137  0.365
2018 Lee-Sherick A, Jacobsen K, Henry CJ, Parker R, Wang X, Frye SV, Earp HS, DeRyckere D, Graham DK. Mertk Inhibition Promotes Anti-Leukemia Immunity By Reversing T Cell Suppression Via the PD-1 Axis Blood. 132: 4019-4019. DOI: 10.1182/Blood-2018-99-119818  0.748
2018 McDaniel NK, Cummings CT, Brand TM, Iida M, Hulse J, Pearson HE, Orbuch RA, Ondracek OJ, Davies KD, Gill P, Wang X, Frye SV, Earp HS, Kimple RJ, Harari PM, ... ... Graham DK, et al. Abstract A140: MERTK mediates intrinsic and adaptive resistance to AXL-targeting agents Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A140  0.52
2017 Branchford BR, Stalker TJ, Law L, Acevedo G, Sather S, Brzezinski C, Wilson KM, Minson K, Lee-Sherick AB, Davizon-Castillo P, Ng C, Zhang W, Neeves KB, Lentz SR, Wang X, ... ... Graham DK, et al. The small molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. Journal of Thrombosis and Haemostasis : Jth. PMID 29045015 DOI: 10.1111/Jth.13875  0.323
2017 Yan D, Wang X, Frye SV, Earp SH, DeRyckere D, Graham DK. Abstract 1082: MerTK promotes resistance to irreversible EGFR TKIs by activation of the PI3K-AKT pathway in NSCLCs expressing wild-type EGFR Cancer Research. 77: 1082-1082. DOI: 10.1158/1538-7445.Am2017-1082  0.51
2016 McIver A, Zhang W, Liu Q, Jiang X, Stashko M, Nichols J, Miley M, Norris-Drouin J, Machius M, DeRyckere D, Wood E, Graham D, Earp HS, Kireev D, Frye S, et al. Discovery of Macrocyclic Pyrimidines as MerTK-specific Inhibitors. Chemmedchem. PMID 28032464 DOI: 10.1002/Cmdc.201600589  0.437
2016 Wang X, Liu J, Zhang W, Stashko MA, Nichols J, Miley MJ, Norris-Drouin J, Chen Z, Machius M, DeRyckere D, Wood E, Graham DK, Earp HS, Kireev D, Frye SV. Design and Synthesis of Novel Macrocyclic Mer Tyrosine Kinase Inhibitors. Acs Medicinal Chemistry Letters. 7: 1044-1049. PMID 27994735 DOI: 10.1021/Acsmedchemlett.6B00221  0.471
2016 Huey MG, Minson KA, Earp HS, DeRyckere D, Graham DK. Targeting the TAM Receptors in Leukemia. Cancers. 8. PMID 27834816 DOI: 10.3390/Cancers8110101  0.542
2016 Sufit A, Lee-Sherick AB, DeRyckere D, Rupji M, Dwivedi B, Varella-Garcia M, Pierce AM, Kowalski J, Wang X, Frye SV, Earp HS, Keating AK, Graham DK. MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme. Plos One. 11: e0165107. PMID 27783662 DOI: 10.1371/Journal.Pone.0165107  0.534
2016 DeRyckere D, Lee Sherick AB, Huey MG, Hill AA, Tyner JW, Jacobsen KM, Page LS, Kirkpatrick GD, Eryildiz F, Montgomery SA, Zhang W, Wang X, Frye SV, Earp HS, Graham DK. UNC2025, a MerTK small molecule inhibitor, is therapeutically effective alone and in combination with methotrexate in leukemia models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27649555 DOI: 10.1158/1078-0432.Ccr-16-1330  0.794
2016 Lee-Sherick AB, Eisenman KM, Sather S, McGranahan A, Armistead PM, McGary CS, Hunsucker SA, Schlegel J, Martinson H, Cannon C, Keating AK, Earp HS, Liang X, DeRyckere D, Graham DK. Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia. Oncogene. PMID 27593932 DOI: 10.1038/onc.2016.295  0.358
2016 Minson KA, Smith CC, DeRyckere D, Libbrecht C, Lee-Sherick AB, Huey MG, Lasater EA, Kirkpatrick GD, Stashko MA, Zhang W, Jordan CT, Kireev D, Wang X, Frye SV, Earp HS, ... ... Graham DK, et al. The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. Jci Insight. 1: e85630. PMID 27158668 DOI: 10.1172/Jci.Insight.85630  0.542
2016 Minson KA, Huey MG, Hill AA, Perez I, Wang X, Frye S, Earp HS, DeRyckere D, Graham DK. Bone Marrow Stromal Cell Mediated Resistance to Mertk Inhibition in Acute Leukemia Blood. 128: 2819-2819. DOI: 10.1182/Blood.V128.22.2819.2819  0.488
2015 Cummings CT, Zhang W, Davies KD, Kirkpatrick GD, Zhang D, DeRyckere D, Wang X, Frye SV, Earp HS, Graham DK. Small molecule inhibition of MERTK is efficacious in non-small cell lung cancer models independent of driver oncogene status. Molecular Cancer Therapeutics. PMID 26162689 DOI: 10.1158/1535-7163.Mct-15-0116  0.748
2015 Lee-Sherick AB, Zhang W, Menachof KK, Hill AA, Rinella S, Kirkpatrick G, Page LS, Stashko MA, Jordan CT, Wei Q, Liu J, Zhang D, DeRyckere D, Wang X, Frye S, ... ... Graham DK, et al. Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia. Oncotarget. 6: 6722-36. PMID 25762638 DOI: 10.18632/Oncotarget.3156  0.55
2015 Alvarez-Calderon F, Gregory MA, Pham-Danis C, DeRyckere D, Stevens BM, Zaberezhnyy V, Hill AA, Gemta L, Kumar A, Kumar V, Wempe MF, Pollyea DA, Jordan CT, Serkova NJ, Graham DK, et al. Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1360-72. PMID 25547679 DOI: 10.1158/1078-0432.Ccr-14-2146  0.448
2015 Graham D, DeRyckere D, Minson K, Smith C, Hill A, Huey M, Lasater E, Wang X, Shah N, Frye S, Shelton Earp H. Development of novel small molecule MerTK and Flt3 tyrosine kinase inhibitors for treatment of acute leukemia Annals of Oncology. 26: ii6. DOI: 10.1093/Annonc/Mdv082.2  0.583
2014 Graham DK, DeRyckere D, Davies KD, Earp HS. The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nature Reviews. Cancer. 14: 769-85. PMID 25568918 DOI: 10.1038/Nrc3847  0.48
2014 Cummings CT, Linger RM, Cohen RA, Sather S, Kirkpatrick GD, Davies KD, DeRyckere D, Earp HS, Graham DK. Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer. Oncotarget. 5: 10434-45. PMID 25372020 DOI: 10.18632/Oncotarget.2142  0.755
2014 Zhang W, DeRyckere D, Hunter D, Liu J, Stashko MA, Minson KA, Cummings CT, Lee M, Glaros TG, Newton DL, Sather S, Zhang D, Kireev D, Janzen WP, Earp HS, ... Graham DK, et al. UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. Journal of Medicinal Chemistry. 57: 7031-41. PMID 25068800 DOI: 10.1021/Jm500749D  0.73
2014 Newton TP, Cummings CT, Graham DK, Bernt KM. Epigenetics and chemoresistance in childhood acute lymphoblastic leukemia International Journal of Hematologic Oncology. 3: 19-30. DOI: 10.2217/Ijh.13.68  0.355
2014 DeRyckere D, Lee-Sherick AB, Hill AA, Page L, Wang X, Frye SV, Earp HS, Graham DK. UNC2025, a Small Molecule MerTK and Flt3 Tyrosine Kinase Inhibitor, Decreases Disease Burden, Prolongs Survival, and Promotes Sensitivity to Chemotherapy in Xenograft Models of Acute Leukemia Blood. 124: 998-998. DOI: 10.1182/Blood.V124.21.998.998  0.564
2014 Minson KA, Smith CC, Lee-Sherick AB, DeRyckere D, Lasater E, Hill AA, Wang X, Frye SV, Earp HS, Shah NP, Graham DK. MRX2843, a Novel Dual MerTK-FLT3 Inhibitor with Activity Against Resistance-Conferring FLT3 Mutations in Acute Myeloid Leukemia Blood. 124: 3757-3757. DOI: 10.1182/Blood.V124.21.3757.3757  0.532
2014 Graham DK, DeRyckere D, Lee-Sherick A, Hill AA, Minson K, Xiaodong W, Zhang W, Liu J, Frye S, Earp HS. Abstract A37: MerTK receptor tyrosine kinase is a therapeutic target in pediatric acute leukemia Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-A37  0.599
2014 Earp HS, Darr D, Zimmermann A, Clark K, Sharpless NE, Bergmeier W, Zhang W, Wang X, DeRyckere D, Frye S, Graham D. Abstract 947: A small molecule Mer tyrosine kinase inhibitor (UNC MerTKi) effectively inhibits growth of murine melanoma Cancer Research. 74: 947-947. DOI: 10.1158/1538-7445.Am2014-947  0.517
2014 Teodorovic LS, Carrico J, DeRyckere D, Zhang W, Wang X, Frye S, Eckhardt SG, Earp HS, Graham DK. Abstract 730: Efficacy of a novel small molecule MER receptor tyrosine kinase inhibitor in B-RAF wild-type and B-RAF mutant melanoma cell lines Cancer Research. 74: 730-730. DOI: 10.1158/1538-7445.Am2014-730  0.493
2014 Jacobsen KM, DeRyckere D, Zhang W, Wang X, Frye SV, Earp HS, Graham DK. Abstract 3637: Targeted inhibition of MER tyrosine kinase in the tumor microenvironment decreases tumor growth in a mouse model of breast cancer Cancer Research. 74: 3637-3637. DOI: 10.1158/1538-7445.Am2014-3637  0.426
2014 Sherick AL, Menachof K, Hill A, Rinella S, DeRyckere D, Liu J, Wang X, Frye S, Earp HS, Graham D. Abstract 1743: A dual FLT-3 and MER tyrosine kinase small molecule inhibitor in acute myeloid leukemia cell lines and patient samples Cancer Research. 74: 1743-1743. DOI: 10.1158/1538-7445.Am2014-1743  0.529
2014 Cummings CT, Davies KD, Carrico J, DeRyckere D, Zhang W, Wang X, Frye S, Earp HS, Graham DK. Abstract 1742: Inhibition of Mer tyrosine kinase with a novel small molecule inhibitor is efficacious in pre-clinical models of non-small cell lung cancer Cancer Research. 74: 1742-1742. DOI: 10.1158/1538-7445.Am2014-1742  0.551
2014 DeRyckere DA, Hill AA, Wang X, Zhang W, Stashko MA, Sather S, Cummings C, Kireev D, Janzen WP, Frye SV, Earp HS, Graham DK. Abstract 1740: Development of a novel small molecule MER tyrosine kinase inhibitor with therapeutic activity in cell culture and mouse models of acute lymphoblastic leukemia Cancer Research. 74: 1740-1740. DOI: 10.1158/1538-7445.Am2014-1740  0.795
2014 Newton TP, Cummings CT, Kirkpatrick GD, Hinz TK, DeRyckere D, Zhang W, Wang X, Frye S, Earp HS, Heasley L, Graham DK. Abstract 1736: A novel Mer tyrosine kinase inhibitor mediates increased cell killing in combination with FGFR inhibition Cancer Research. 74: 1736-1736. DOI: 10.1158/1538-7445.Am2014-1736  0.588
2014 Wu J, Huey L, Bash RE, Cohen SM, Ewend MG, Wang X, Graham DK, Frye SV, Earp HS, Miller CR. NT-38 * MerTK AS A TARGET IN GLIOBLASTOMA Neuro-Oncology. 16: v166-v167. DOI: 10.1093/Neuonc/Nou265.36  0.473
2014 Liu J, Yang C, Simpson C, DeRyckere D, Deusen AV, Miley MJ, Kireev D, Norris-Drouin J, Sather S, Hunter D, Korboukh VK, Patel HS, Janzen WP, Machius M, Johnson GL, ... ... Graham DK, et al. Correction to Discovery of Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia Acs Medicinal Chemistry Letters. 5: 1173-1173. DOI: 10.1021/Ml500328M  0.434
2014 Zhang W, Zhang D, Stashko MA, DeRyckere D, Hunter D, Kireev D, Miley MJ, Cummings C, Lee M, Norris-Drouin J, Stewart WM, Sather S, Zhou Y, Kirkpatrick G, Machius M, ... ... Graham DK, et al. Correction to Pseudo-Cyclization through Intramolecular Hydrogen Bond Enables Discovery of Pyridine Substituted Pyrimidines as New Mer Kinase Inhibitors Journal of Medicinal Chemistry. 57: 7141-7141. DOI: 10.1021/Jm501216S  0.326
2013 Zhang W, McIver AL, Stashko MA, DeRyckere D, Branchford BR, Hunter D, Kireev D, Miley MJ, Norris-Drouin J, Stewart WM, Lee M, Sather S, Zhou Y, Di Paola JA, Machius M, ... ... Graham DK, et al. Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis. Journal of Medicinal Chemistry. 56: 9693-700. PMID 24219778 DOI: 10.1021/Jm501217P  0.461
2013 Zhang W, Zhang D, Stashko MA, DeRyckere D, Hunter D, Kireev D, Miley MJ, Cummings C, Lee M, Norris-Drouin J, Stewart WM, Sather S, Zhou Y, Kirkpatrick G, Machius M, ... ... Graham DK, et al. Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors. Journal of Medicinal Chemistry. 56: 9683-92. PMID 24195762 DOI: 10.1021/Jm401387J  0.758
2013 Christoph S, Lee-Sherick AB, Sather S, DeRyckere D, Graham DK. Pre-clinical evaluation of tyrosine kinase inhibitors for treatment of acute leukemia. Journal of Visualized Experiments : Jove. e50720. PMID 24084362 DOI: 10.3791/50720  0.541
2013 Christoph S, Deryckere D, Schlegel J, Frazer JK, Batchelor LA, Trakhimets AY, Sather S, Hunter DM, Cummings CT, Liu J, Yang C, Kireev D, Simpson C, Norris-Drouin J, Hull-Ryde EA, ... ... Graham DK, et al. UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. Molecular Cancer Therapeutics. 12: 2367-77. PMID 23997116 DOI: 10.1158/1535-7163.Mct-13-0040  0.82
2013 Cook RS, Jacobsen KM, Wofford AM, DeRyckere D, Stanford J, Prieto AL, Redente E, Sandahl M, Hunter DM, Strunk KE, Graham DK, Earp HS. MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis. The Journal of Clinical Investigation. 123: 3231-42. PMID 23867499 DOI: 10.1172/Jci67655  0.762
2013 Linger RM, Lee-Sherick AB, DeRyckere D, Cohen RA, Jacobsen KM, McGranahan A, Brandão LN, Winges A, Sawczyn KK, Liang X, Keating AK, Tan AC, Earp HS, Graham DK. Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia. Blood. 122: 1599-609. PMID 23861246 DOI: 10.1182/Blood-2013-01-478156  0.81
2013 Cummings CT, Deryckere D, Earp HS, Graham DK. Molecular pathways: MERTK signaling in cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5275-80. PMID 23833304 DOI: 10.1158/1078-0432.Ccr-12-1451  0.747
2013 Liu J, Zhang W, Stashko MA, Deryckere D, Cummings CT, Hunter D, Yang C, Jayakody CN, Cheng N, Simpson C, Norris-Drouin J, Sather S, Kireev D, Janzen WP, Earp HS, ... Graham DK, et al. UNC1062, a new and potent Mer inhibitor. European Journal of Medicinal Chemistry. 65: 83-93. PMID 23693152 DOI: 10.1016/J.Ejmech.2013.03.035  0.755
2013 Liang X, Branchford B, Greffe B, McGavran L, Carstens B, Meltesen L, Albano EA, Quinones R, Cook B, Graham DK. Dual ALK and MYC rearrangements leading to an aggressive variant of anaplastic large cell lymphoma. Journal of Pediatric Hematology/Oncology. 35: e209-13. PMID 23619105 DOI: 10.1097/Mph.0B013E3182815046  0.397
2013 Schlegel J, Sambade MJ, Sather S, Moschos SJ, Tan AC, Winges A, DeRyckere D, Carson CC, Trembath DG, Tentler JJ, Eckhardt SG, Kuan PF, Hamilton RL, Duncan LM, Miller CR, ... ... Graham DK, et al. MERTK receptor tyrosine kinase is a therapeutic target in melanoma. The Journal of Clinical Investigation. 123: 2257-67. PMID 23585477 DOI: 10.1172/Jci67816  0.725
2013 Ware KE, Hinz TK, Kleczko E, Singleton KR, Marek LA, Helfrich BA, Cummings CT, Graham DK, Astling D, Tan AC, Heasley LE. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis. 2: e39. PMID 23552882 DOI: 10.1038/oncsis.2013.4  0.332
2013 Lee-Sherick AB, Eisenman KM, Sather S, McGranahan A, Armistead PM, McGary CS, Hunsucker SA, Schlegel J, Martinson H, Cannon C, Keating AK, Earp HS, Liang X, DeRyckere D, Graham DK. Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia. Oncogene. 32: 5359-68. PMID 23474756 DOI: 10.1038/Onc.2013.40  0.677
2013 Brandao LN, Winges A, Christoph S, Sather S, Migdall-Wilson J, Schlegel J, McGranahan A, Gao D, Liang X, Deryckere D, Graham DK. Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia. Blood Cancer Journal. 3: e101. PMID 23353780 DOI: 10.1038/Bcj.2012.46  0.792
2013 Christoph S, Schlegel J, Alvarez-Calderon F, Kim YM, Brandao LN, DeRyckere D, Graham DK. Bioluminescence imaging of leukemia cell lines in vitro and in mouse xenografts: effects of monoclonal and polyclonal cell populations on intensity and kinetics of photon emission. Journal of Hematology & Oncology. 6: 10. PMID 23343252 DOI: 10.1186/1756-8722-6-10  0.616
2013 Linger RM, Cohen RA, Cummings CT, Sather S, Migdall-Wilson J, Middleton DH, Lu X, Barón AE, Franklin WA, Merrick DT, Jedlicka P, DeRyckere D, Heasley LE, Graham DK. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer. Oncogene. 32: 3420-31. PMID 22890323 DOI: 10.1038/Onc.2012.355  0.808
2013 Graham DK. MerTK receptor tyrosine kinase is a therapeutic target in acute myeloid leukemia Journal of Blood Disorders and Transfusion. DOI: 10.4172/2155-9864.S1.002  0.463
2013 Lee-Sherick AB, Menachof K, Hill AA, Rinella S, Liu J, DeRyckere D, Wang X, Frye SV, Earp HS, Graham DK. UNC1666, a Dual Mer and Flt-3 Tyrosine Kinase Small Molecule Inhibitor In Acute Myeloid Leukemia Blood. 122: 3849-3849. DOI: 10.1182/Blood.V122.21.3849.3849  0.512
2013 Acevedo G, Branchford BR, Law L, Brzezinski C, Sather S, Brodsky G, DeRyckere D, Zhang W, Earp HS, Frye SV, Graham DK, Di Paola J. Novel Small Molecule Inhibitors Of The Gas6/TAM Signaling Pathway Mediate Synergistic Inhibition Of Platelet Aggregation In Combination With ADP/P2Y Antagonists Blood. 122: 3507-3507. DOI: 10.1182/Blood.V122.21.3507.3507  0.395
2013 DeRyckere D, Wang X, Hill AA, Zhang W, Stashko MA, Sather S, Cummings CE, Janzen WP, Frye SV, Earp HS, Graham DK. Development Of a Novel Small Molecule Inhibitor Of The Mer Tyrosine Kinase For Treatment Of Acute Lymphoblastic Leukemia Blood. 122: 2666-2666. DOI: 10.1182/Blood.V122.21.2666.2666  0.547
2013 Acevedo G, Branchford BR, Brzezinski C, Sather S, Brodsky G, DeRyckere D, Zhang W, Liu J, Earp HS, Wang X, Frye SV, Graham DK, Di Paola J. Novel Small Molecule Inhibitors Of The Gas6/TAM Signaling Pathway Inhibit Platelet Aggregation In Vitro and Protect Mice From Arterial and Venous Thrombosis In Vivo Blood. 122: 2296-2296. DOI: 10.1182/Blood.V122.21.2296.2296  0.376
2013 Christoph S, Maag S, DeRyckere D, Graham DK, Frye SV, Earp HS, Liu J, Yang C, Zhang W, Wang X, Elmaagacli AH, Beelen D. Mer Receptor Tyrosine Kinase Is a Novel Therapeutic Target In Multiple Myeloma Blood. 122: 1957-1957. DOI: 10.1182/Blood.V122.21.1957.1957  0.501
2013 Jacobsen KM, Cook RS, DeRyckere D, Stanford J, Hunter DM, Wang X, Frye S, Graham DK, Earp HS. Abstract A110: Inhibition of MerTK in tumor infiltrating leukocytes decreases tumor growth in a mouse model of breast cancer Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-A110  0.404
2013 Schlegel J, Sambade M, Sather S, Moschos S, Tan A, Winges A, DeRyckere D, Carson CC, Trembath DG, Tentler JJ, Eckhardt G, Kuan P, Hamilton RL, Duncan LM, Miller CR, ... ... Graham DK, et al. Abstract 3037: Mer receptor tyrosine kinase is a novel therapeutic target in melanoma. Cancer Research. 73: 3037-3037. DOI: 10.1158/1538-7445.Am2013-3037  0.54
2012 Liu J, Yang C, Simpson C, Deryckere D, Van Deusen A, Miley MJ, Kireev D, Norris-Drouin J, Sather S, Hunter D, Korboukh VK, Patel HS, Janzen WP, Machius M, Johnson GL, ... ... Graham DK, et al. Discovery of Novel Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia. Acs Medicinal Chemistry Letters. 3: 129-134. PMID 22662287 DOI: 10.1021/Ml200239K  0.507
2012 Migdall-Wilson J, Bates C, Schlegel J, Brandão L, Linger RM, DeRyckere D, Graham DK. Prolonged exposure to a Mer ligand in leukemia: Gas6 favors expression of a partial Mer glycoform and reveals a novel role for Mer in the nucleus. Plos One. 7: e31635. PMID 22363695 DOI: 10.1371/Journal.Pone.0031635  0.783
2012 Rogers AE, Le JP, Sather S, Pernu BM, Graham DK, Pierce AM, Keating AK. Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology. Oncogene. 31: 4171-81. PMID 22179835 DOI: 10.1038/Onc.2011.588  0.507
2012 Branchford BR, Law L, Sather S, Brodsky G, Earp HS, Wang X, Frye S, Graham DK, Di Paola JA. A Small Molecule Inhibitor of the Gas6/Mer Pathway Inhibits Platelet Activation and Thrombosis with Equal Efficacy to, but Greater Potency Than, iMer, the Novel MerTK Splice Variant Blood. 120: 3303-3303. DOI: 10.1182/Blood.V120.21.3303.3303  0.363
2012 Christoph S, DeRyckere D, Schlegel J, Sather S, McGranahan A, Franzer JK, Trakhimets A, Wang X, Kireev D, Janzen W, Liu J, Yang C, Simpson C, Norris-Drouin J, Frye S, ... ... Graham DK, et al. Evaluation of UNC569, a Novel Small Molecule Mer Inhibitor for the Treatment of ALL in Vitro and in Vivo. Blood. 120: 2607-2607. DOI: 10.1182/Blood.V120.21.2607.2607  0.672
2012 Lee-Sherick AB, Menachof K, Eisenman KM, McGranahan A, McGary C, Hunsucker SA, Schlegel J, Armistead PM, Liang X, Kireev D, Janzen W, Liu J, Stashko M, Norris-Drouin J, Earp HS, ... ... Graham DK, et al. Mer Receptor Tyrosine Kinase Is A Potential Therapeutic Target in Acute Myeloid Leukemia Blood. 120: 1317-1317. DOI: 10.1182/Blood.V120.21.1317.1317  0.712
2012 Linger RMA, DeRyckere D, Brandão L, Sawczyn KK, Jacobsen KM, Liang X, Keating AK, Graham DK. Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia (Blood (2009) 114, 13 (2678-2687)) Blood. 120: 1533. DOI: 10.1182/blood-2012-06-440792  0.384
2012 Liu J, Yang C, Simpson C, Deryckere D, Van Deusen A, Miley MJ, Kireev D, Norris-Drouin J, Sather S, Hunter D, Korboukh VK, Patel HS, Janzen WP, MacHius M, Johnson GL, ... ... Graham DK, et al. Discovery of small molecule Mer kinase inhibitors for the treatment of pediatric acute lymphoblastic leukemia Acs Medicinal Chemistry Letters. 3: 129-134. DOI: 10.1021/ml200239k  0.329
2011 Brandão L, Migdall-Wilson J, Eisenman K, Graham DK. TAM receptors in leukemia: expression, signaling, and therapeutic implications. Critical Reviews in Oncogenesis. 16: 47-63. PMID 22150307 DOI: 10.1615/Critrevoncog.V16.I1-2.60  0.792
2011 Liang X, Greffe B, Cook B, Giller R, Graham DK, McGranahan AN, Wang M. Gray zone lymphomas in pediatric patients. Pediatric and Developmental Pathology : the Official Journal of the Society For Pediatric Pathology and the Paediatric Pathology Society. 14: 57-63. PMID 20331368 DOI: 10.2350/09-10-0724-Cr.1  0.31
2011 Jacobsen K, Linger R, Graham D. TYRO3 (TYRO3 protein tyrosine kinase) Atlas of Genetics and Cytogenetics in Oncology and Haematology. DOI: 10.4267/2042/44892  0.739
2011 Christoph S, DeRyckere D, Sather S, Wang X, Kireev D, Janzen W, Liu J, Yang C, van Deusen A, Simpson C, Norris-Drouin J, Frye S, Earp HS, Johnson GL, Graham DK. UNC569 As Novel Small Molecule Mer Receptor Tyrosine Kinase Inhibitor for Treatment of ALL Blood. 118: 2589-2589. DOI: 10.1182/Blood.V118.21.2589.2589  0.537
2011 Branchford BR, Sather S, Brodsky G, White-Adams TC, DeRyckere D, Neeves KB, Wilson KM, Lentz SR, Graham DK, Di Paola JA. Imer Blocks Phosphorylation of the β3 Integrin, Decreasing Platelet Activation Responses and Protecting Mice From Arterial Thrombosis Blood. 118: 189-189. DOI: 10.1182/Blood.V118.21.189.189  0.339
2011 Lee-Sherick AB, Eisenman KM, Sather S, DeRyckere D, Schlegel J, Graham DK. Mer Receptor Tyrosine Kinase Is Over-Expressed In and Contributes to Oncogenesis In Acute Myeloid Leukemia Blood. 118: 1390-1390. DOI: 10.1182/Blood.V118.21.1390.1390  0.719
2010 Lee-Sherick AB, Linger RM, Gore L, Keating AK, Graham DK. Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development. British Journal of Haematology. 151: 295-311. PMID 20813012 DOI: 10.1111/J.1365-2141.2010.08282.X  0.431
2010 Linger RM, Keating AK, Earp HS, Graham DK. Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opinion On Therapeutic Targets. 14: 1073-90. PMID 20809868 DOI: 10.1517/14728222.2010.515980  0.511
2010 Keating AK, Kim GK, Jones AE, Donson AM, Ware K, Mulcahy JM, Salzberg DB, Foreman NK, Liang X, Thorburn A, Graham DK. Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Molecular Cancer Therapeutics. 9: 1298-307. PMID 20423999 DOI: 10.1158/1535-7163.Mct-09-0707  0.554
2010 Liang X, Lovell MA, Capocelli KE, Albano EA, Birch S, Keating AK, Graham DK. Thymoma in children: report of 2 cases and review of the literature. Pediatric and Developmental Pathology : the Official Journal of the Society For Pediatric Pathology and the Paediatric Pathology Society. 13: 202-8. PMID 20055684 DOI: 10.2350/09-07-0672-Oa.1  0.302
2009 Linger RM, DeRyckere D, Brandão L, Sawczyn KK, Jacobsen KM, Liang X, Keating AK, Graham DK. Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia. Blood. 114: 2678-87. PMID 19643988 DOI: 10.1182/Blood-2009-03-209247  0.819
2009 Anwar A, Keating AK, Joung D, Sather S, Kim GK, Sawczyn KK, Brandão L, Henson PM, Graham DK. Mer tyrosine kinase (MerTK) promotes macrophage survival following exposure to oxidative stress. Journal of Leukocyte Biology. 86: 73-9. PMID 19386698 DOI: 10.1189/Jlb.0608334  0.383
2008 Macy ME, Sawczyn KK, Garrington TP, Graham DK, Gore L. Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials. Current Oncology Reports. 10: 477-90. PMID 18928662 DOI: 10.1007/S11912-008-0073-0  0.359
2008 Linger RM, Keating AK, Earp HS, Graham DK. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Advances in Cancer Research. 100: 35-83. PMID 18620092 DOI: 10.1016/S0065-230X(08)00002-X  0.46
2008 Liang X, Graham DK. Natural killer cell neoplasms. Cancer. 112: 1425-36. PMID 18286525 DOI: 10.1002/Cncr.23316  0.32
2008 Liang X, Greffe B, Garrington T, Graham DK. Precursor natural killer cell leukemia. Pediatric Blood & Cancer. 50: 876-8. PMID 17417789 DOI: 10.1002/Pbc.21189  0.358
2008 Linger RM, DeRyckere D, Brandão L, Sawczyn KK, Keating AK, Graham DK. Synergistic Killing of E2A-PBX1+ B-ALL Cells by Chemotherapeutic Agents and MerTK Inhibition Blood. 112: 2843-2843. DOI: 10.1182/Blood.V112.11.2843.2843  0.534
2007 Sather S, Kenyon KD, Lefkowitz JB, Liang X, Varnum BC, Henson PM, Graham DK. A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood. 109: 1026-33. PMID 17047157 DOI: 10.1182/Blood-2006-05-021634  0.422
2007 Sawczyn KK, Porter CC, DeGregori J, Graham DK. Ectopic expression and oncogenesis of Mer tyrosine kinase in E2A-PBX1 expressing B-cell acute lymphoblastic leukemia Journal of Clinical Oncology. 25: 9561-9561. DOI: 10.1200/Jco.2007.25.18_Suppl.9561  0.437
2006 Graham DK, Salzberg DB, Kurtzberg J, Sather S, Matsushima GK, Keating AK, Liang X, Lovell MA, Williams SA, Dawson TL, Schell MJ, Anwar AA, Snodgrass HR, Earp HS. Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 2662-9. PMID 16675557 DOI: 10.1158/1078-0432.Ccr-05-2208  0.472
2006 Keating AK, Salzberg DB, Sather S, Liang X, Nickoloff S, Anwar A, Deryckere D, Hill K, Joung D, Sawczyn KK, Park J, Curran-Everett D, McGavran L, Meltesen L, Gore L, ... ... Graham DK, et al. Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase. Oncogene. 25: 6092-100. PMID 16652142 DOI: 10.1038/Sj.Onc.1209633  0.513
2005 Keating AK, Sather S, Donson A, Straessle J, Cao JZ, Foreman N, Graham DK. Expression of Mer and Axl receptor tyrosine kinases in pediatric astrocytoma patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 1555. PMID 27946936 DOI: 10.1200/Jco.2005.23.16_Suppl.1555  0.47
2005 Salzberg DB, Keating AK, Anwar A, Sawczyn K, Hill K, Sather S, Park J, DeRyckere D, Everett D, Graham DK. Lymphoblastic Leukemia/Lymphoma in Mice Overexpressing the Mer Receptor Tyrosine Kinase. Blood. 106: 2619-2619. DOI: 10.1182/Blood.V106.11.2619.2619  0.53
2004 Salzberg DB, Keating AK, Cao J, Sather S, Hill K, Anwar A, Graham DK. Ectopic Expression of Mer Receptor Tyrosine Kinase in Childhood T Cell Acute Lymphoblastic Leukemia. Blood. 104: 4310-4310. DOI: 10.1182/Blood.V104.11.4310.4310  0.468
2004 Graham DK, Sather S. A Soluble Truncated Form of the Mer Tyrosine Kinase Inhibits Gas6 Activity in Platelets and Monocytes. Blood. 104: 1561-1561. DOI: 10.1182/blood.v104.11.1561.1561  0.305
2003 Graham DK, Liang X, Miller KL, Wei Q, Stork LC. Disseminated nasopharyngeal natural killer cell lymphoblastic lymphoma in a child. Medical and Pediatric Oncology. 40: 251-3. PMID 12555256 DOI: 10.1002/Mpo.10138  0.312
1995 Lai KS, Jin Y, Graham DK, Witthuhn BA, Ihle JN, Liu ET. A kinase-deficient splice variant of the human JAK3 is expressed in hematopoietic and epithelial cancer cells. The Journal of Biological Chemistry. 270: 25028-36. PMID 7559633 DOI: 10.1074/Jbc.270.42.25028  0.332
1994 Graham DK, Dawson TL, Mullaney DL, Snodgrass HR, Earp HS. Cloning and mRNA expression analysis of a novel human protooncogene, c-mer. Cell Growth & Differentiation : the Molecular Biology Journal of the American Association For Cancer Research. 5: 647-57. PMID 8086340  0.336
1994 Neubauer A, Fiebeler A, Graham DK, O'Bryan JP, Schmidt CA, Barckow P, Serke S, Siegert W, Snodgrass HR, Huhn D. Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis. Blood. 84: 1931-41. PMID 7521695 DOI: 10.1182/Blood.V84.6.1931.Bloodjournal8461931  0.47
Show low-probability matches.